Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant 2016 Jan;51(1):2-12
Date
07/21/2015Pubmed ID
26191950DOI
10.1038/bmt.2015.164Scopus ID
2-s2.0-84953346101 (requires institutional sign-in at Scopus site) 21 CitationsAbstract
Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sensitive methods to measure or detect such disease have been evaluated, including multi-parametric flow cytometry, PCR, next-generation sequencing and imaging modalities. The following literature review examines current methods for detecting and monitoring minimal or measurable residual disease (MRD) in the post-transplant setting. Improved methods for detecting MRD will refine the current definitions of remission and could guide treatment approaches.
Author List
Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RFAuthor
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsAutografts
High-Throughput Nucleotide Sequencing
Humans
Multiple Myeloma
Multiplex Polymerase Chain Reaction
Neoplasm, Residual
Stem Cell Transplantation
